Pembrolizumab After Thyroidectomy for Anaplastic Thyroid Carcinoma
Yes, pembrolizumab can and should be administered after thyroidectomy for anaplastic thyroid carcinoma (ATC), particularly in the metastatic or unresectable residual disease setting, as part of a multimodal treatment strategy that includes radiotherapy and systemic therapy. 1
Treatment Context and Timing
The use of pembrolizumab in ATC is specifically indicated for metastatic disease rather than as adjuvant therapy following complete resection. The NCCN Guidelines 2025 explicitly recommend PD-1 inhibitors (pembrolizumab, nivolumab) for patients with metastatic ATC, with the strongest evidence supporting their use regardless of tumor mutational burden (TMB) or combined positive score (CPS) 1. This recommendation is extrapolated from trials showing objective response rates of approximately 19% with spartalizumab, with higher response rates in PD-L1-positive patients (29% for any PD-L1 expression, 35% for PD-L1 ≥50%) 1.
Clinical Scenarios for Post-Thyroidectomy Pembrolizumab
Scenario 1: Residual or Unresectable Disease After Surgery
When thyroidectomy achieves R0/R1 resection but residual disease remains (particularly in the cricoid cartilage, trachea, or other structures), pembrolizumab should be initiated alongside radiotherapy 2. The French ENDOCAN-TUTHYREF guidelines emphasize that systemic therapy must begin within the first 10 days of diagnostic suspicion and should not be delayed by locoregional treatments 2.
Scenario 2: Metastatic Disease Present at Surgery
For patients with distant metastases identified at the time of thyroidectomy, pembrolizumab represents a critical treatment option. Real-world data demonstrates median overall survival of 7.7 months and median progression-free survival of 6.2 months with lenvatinib plus pembrolizumab in BRAF wild-type ATC 3. The confirmed overall response rate was 36%, with 9% achieving complete response 3.
Scenario 3: BRAF Wild-Type vs BRAF-Mutated Disease
- BRAF wild-type ATC: First-line treatment should be lenvatinib plus pembrolizumab, which shows superior efficacy compared to chemotherapy alone 1, 3
- BRAF V600E-mutated ATC: Targeted therapy with dabrafenib/trametinib takes priority, with pembrolizumab reserved for second-line treatment or combination therapy 2
Combination Strategies
Pembrolizumab plus lenvatinib is the preferred immunotherapy approach for metastatic ATC. A retrospective study of 6 patients showed 66% complete response rate with median PFS of 16.5 months, particularly in patients with increased TMB or PD-L1 TPS >50% 1. Real-world Italian data confirmed median OS of 10 months and PFS of 6 months with this combination, achieving an objective response rate of 37.5% 4.
Pembrolizumab with chemotherapy (nab-paclitaxel and carboplatin) has demonstrated sustained near-complete response lasting over 30 months in PD-L1-positive (TPS 80%) BRAF wild-type ATC 5. This triplet regimen may be considered when lenvatinib is contraindicated or not tolerated.
Critical Treatment Principles
Radiotherapy Integration
Pembrolizumab should be combined with cervical-mediastinal radiotherapy (>50-60 Gy) when treating locoregional disease post-thyroidectomy 2. The "boosted abscopal effect" from radiotherapy plus pembrolizumab has been documented, with one case achieving complete response of both local and distant disease after 2 cycles 6.
PD-L1 Testing
While pembrolizumab can be used regardless of PD-L1 status in ATC 1, PD-L1 expression correlates with better outcomes. Testing should be performed using combined positive score (CPS), which accounts for both tumor and immune microenvironment 2. Response rates are highest when PD-L1 expression is ≥50% 1.
Biomarker Considerations
Beyond PD-L1, evaluate:
- Tumor mutational burden (TMB): Higher TMB correlates with better pembrolizumab response 1
- Microsatellite instability (MSI): MSI-high status predicts enhanced immunotherapy benefit 2
- Nutritional status: CONUT score ≤2 predicts significantly longer OS and PFS compared to CONUT ≥3 4
Safety Profile and Management
Common adverse events include:
- Immune-related toxicities: Pneumonitis and colitis are the most serious, leading to pembrolizumab discontinuation in 14% of patients 3
- Lenvatinib-specific toxicities: Concern for esophageal or tracheal fistula requires careful monitoring, though actual fistula formation is rare 3
- Dose modifications: Median initial lenvatinib dose is 16 mg (range 10-20 mg), often lower than the standard 24 mg due to toxicity concerns 3
Contraindications to Pembrolizumab Post-Thyroidectomy
Pembrolizumab should not be used as adjuvant therapy following complete (R0) resection of ATC without evidence of residual or metastatic disease. The FDA label for pembrolizumab does not include an indication for adjuvant treatment of thyroid cancer 7. The drug is specifically indicated for unresectable or metastatic disease settings.
Practical Algorithm
Step 1: Confirm ATC diagnosis with reflex molecular testing (BRAF, RET, ALK, PD-L1, TMB, MSI) 2
Step 2: Assess disease extent post-thyroidectomy:
- R0 resection, no metastases → Radiotherapy alone, close surveillance
- R1/R2 resection or unresectable residual → Radiotherapy + pembrolizumab ± lenvatinib
- Distant metastases present → Lenvatinib + pembrolizumab (first-line for BRAF wild-type)
Step 3: Initiate systemic therapy within 10 days of diagnosis 2
Step 4: Pembrolizumab dosing: 200 mg IV every 3 weeks or 400 mg IV every 6 weeks 3
Step 5: Response assessment every 4-6 weeks with CT and FDG-PET 2
This approach prioritizes survival and quality of life by recognizing that ATC has a median survival of only 5 months without aggressive multimodal therapy 8, and pembrolizumab-based regimens can extend this to 7-10 months with meaningful response rates 4, 3.